Valganciclovir Hydrochloride NDC 72603-750

NDC codes

FDA NDC Directory

Product NDC (as listed)72603-750Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72603-0750Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72603-750-01	72603075001	60 TABLET in 1 BOTTLE (72603-750-01)Marketed from Mar 1, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Valganciclovir Hydrochloride
Generic name (nonproprietary): valganciclovir hydrochloride
Active ingredients: Valganciclovir hydrochloride — 450 mg/1
Dosage form: Tablet
Route: Oral
Labeler: NorthStar Rx LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 204750
Marketing start: Mar 1, 2026
Listing expires: Dec 31, 2027
Other FDA classes: DNA Polymerase Inhibitors (Mechanism)Nucleoside Analog (EXT)
Identifiers: Product ID 72603-750_1cc09039-dcd6-4721-abd4-411535ccf442SPL ID 1cc09039-dcd6-4721-abd4-411535ccf442SPL set ID 1cc09039-dcd6-4721-abd4-411535ccf442RxCUI 313566UNII 4P3T9QF9NZ
Pharmacologic class: Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor; Nucleoside Analog Antiviral

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472603075001 followed by a unit qualifier and the quantity

Package 72603-0750-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 20, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Valganciclovir tablets are a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients ( 1.2 ) Prevention of CMV disease in kidney and heart transplant patients at high risk. 1.1 Adult Patients Treatment of Cytomegalovirus (CMV) Retinitis: Valganciclovir tablets are indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) [see Clinical Studies (14.1) ] . Prevention of CMV Disease: Valganciclovi…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 204750

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 204750
Product	Strength	Form · route	Labeler	Product NDC
Valganciclovir Hydrochloride	Valganciclovir hydrochloride 450 mg/1	TabletOral	Aurobindo Pharma Limited	65862-753